Pfizer Inc PFE.N and its associate BioNTech SE BNTX.O mentioned on Tuesday that they’d submitted an utility to the U.S. well being regulator for the authorization of a booster dose of their COVID-19 vaccine for kids aged 5 to 11 years.
The businesses earlier this month reported information from a mid-to-late stage research exhibiting a 3rd dose of their shot elevated safety in opposition to the unique coronavirus model and the Omicron variant amongst youngsters within the age group.
It’s unclear how a lot demand there may be for a 3rd vaccine dose within the age group. Simply 28% of youngsters aged 5 to 11 years – round 8.2 million – are absolutely vaccinated, in accordance with information from the U.S. Facilities for Illness Management and Prevention.
There has additionally been some skepticism on the necessity for boosters in youthful youngsters given the diminished threat of extreme an infection and hospitalization within the age group.
No COVID-19 take a look at for unvaccinated youngsters coming into Canada
Pfizer and BioNTech have filed for the clearance of a 10-microgram booster dose for kids 5 to 11 years. Adults obtain a 30-microgram dose of the vaccine.
The first two-dose COVID-19 shot from Pfizer and BioNTech was licensed in the US for kids 5 to 11 years in October.
Vaccination charges stall for Canadian youngsters aged 5 to 11
Rival Moderna Inc MRNA.O remains to be ready for a call from U.S. regulators on the usage of its main COVID-19 collection amongst age teams beneath 18 years.
It plans to submit an utility to the FDA for the authorization of its COVID-19 vaccine amongst youngsters six months to 5 years by the tip of April.
(Reporting by Amruta Khandekar; Enhancing by Aditya Soni and Sriraj Kalluvila)